Theriva Biologics, Inc.
TOVX
$0.21
-$0.01-5.94%
AMEX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -88.76% | 682.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -71.01% | 198.73% | |||
| Operating Income | 71.01% | -198.73% | |||
| Income Before Tax | 66.60% | -201.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 66.60% | -201.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.60% | -201.99% | |||
| EBIT | 71.01% | -198.73% | |||
| EBITDA | 71.16% | -199.89% | |||
| EPS Basic | 76.69% | -24.43% | |||
| Normalized Basic EPS | 80.07% | -25.04% | |||
| EPS Diluted | 76.69% | -24.43% | |||
| Normalized Diluted EPS | 80.07% | -25.04% | |||
| Average Basic Shares Outstanding | 43.29% | 142.70% | |||
| Average Diluted Shares Outstanding | 43.29% | 142.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||